DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mustargen (Mechlorethamine Hydrochloride (Nitrogen Mustard)) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

MUSTARGEN drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

OVERDOSAGE

With total doses exceeding 0.4 mg/kg of body weight for a single course, severe leukopenia, anemia, thrombocytopenia and a hemorrhagic diathesis with subsequent delayed bleeding may develop. Death may follow. The only treatment in instances of excessive dosage appears to be repeated blood product transfusions, antibiotic treatment of complicating infections and general supportive measures.

The intravenous LD50 of MUSTARGEN is 2 mg/kg and 1.6 mg/kg in the mouse and rat, respectively. The oral LD50 for mechlorethamine hydrochloride is 20 mg/kg and 10 mg/kg in the mouse and rat, respectively.

CONTRAINDICATIONS

The use of MUSTARGEN is contraindicated in the presence of known infectious diseases and in patients who have had previous anaphylactic reactions to MUSTARGEN.

REFERENCES

  1. Calabresi, P.; Parks, R.E., Jr.: Antiproliferative agents and drugs used for immunosuppression, in “The Pharmacological Basis of Therapeutics”, L.S. Goodman; A. Gilman (eds.), Ed. 6, New York, Macmillan, 1980, p. 1263.
  2. Kolygin, B.A.: Combination chemotherapy of Hodgkin’s disease in children, CancerPhiladelphia 38:1494-1497, Oct. 1976.
  3. Young, R.C.; DeVita, V.T.; Johnson, R.E.: Hodgkin’s disease in childhood, Blood 42: 163-174, Aug. 1973.
  4. Bass, B.H.: Nitrogen mustard in the palliation of lung cancer, Brit. Med. J. 1: 617-620, Feb. 27, 1960.
  5. Bonte, F.J.; Storaasli, J.P.; Weisberger, A.S.: Comparative evaluation of radioactive colloidal gold and nitrogen mustard in the treatment of serous effusions of neoplastic origin, Radiol. 67: 63-66, July 1956.
  6. Fullerton, C.W.; Reed, P.I.: Nitrogen mustard in treatment of pleural and peritoneal effusions, Can. Med. Ass. J. 79: 190-191, Aug. 1, 1958.
  7. Harris, M.S.: The use of chemotherapy for carcinoma of the lung, J. Int. Coll. Surg. 34: 666-673, Nov. 1960.
  8. Hepper, N.G.G.; Carr, D.T.: Intrapleural use of nitrogen mustard in malignant pleural effusion, Minn.Med. 43: 374-376, June 1960.
  9. Levison, V.B.: Nitrogen mustard in palliation of malignant effusions, Brit. Med. J. 1:1143-1145, Apr. 22, 1961.
  10. Taylor, L.: A technique for intrapleural administration of nitrogen mustard compounds, Amer. J. Med. Sci. 233: 538-541, May 1957.
  11. Weisberger, A.S.: Direct instillation of nitrogen mustard in the management of malignant effusions, Ann. N.Y. Acad. Sci. 68: 1091-1096, Apr. 24, 1958.
  12. Weisberger, A.S.; Bonte, F.J.; Suhrland, L.G.: Management of malignant serous effusions, Geriat. 11: 23-30, Jan. 1956.
  13. Weisberger, A.S.; Levine, B.; Storaasli, J.P.: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin, J. Amer. Med. Ass. 159: 1704-1707, Dec. 31, 1958.
  14. Brown, F.E.; Wright, H.K.: Hypovolemia following intraperitoneal nitrogen mustard therapy, Surg. Gynecol. & Obstet. 121: 528-530, Sept. 1965.
  15. Greenwald, E.S.: Cancer chemotherapy, N.Y. Med. J. 66: 2532-2548, Oct. 1, 1966.
  16. Rohn, R.J.; Bond, W.H.: Some indications for the use of chemotherapy in neoplastic disorders, J. Ind. Med. Ass. 50: 417-428, Apr. 1957.
  17. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs, NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402.
  18. AMA Council Report: Guidelines for Handling Parenteral Antineoplastics, JAMA 253: 1590-1592,1985.
  19. National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc. D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
  20. Clinical Oncological Society of Australia: Guidelines and recommendations for safe handling of antineoplastic agents, Med. J. Australia 1: 426-428, 1983.
  21. Jones, R.B., et al: Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center, Ca - A Cancer Journal for Clinicians Sept/Oct, 258-263, 1983.
  22. American Society of Hospital Pharmacists: Technical assistance bulletin on handling cytotoxic and hazardous drugs, Am. J. Hosp. Pharm. 47: 1033-1049, 1995.
  23. Controlling Occupational Exposure to Hazardous Drugs (OSHA Work-Practice Guidelines), Am. J. Health-Syst. Pharm. 53: 1669-1685, 1996.

Manufactured by: Baxter Oncology GmbH, 33790 Halle/Westfalen, Germany

For: Recordati Rare Diseases Inc., Lebanon, NJ 08833, U.S.A.

® Trademark of Recordati Rare Diseases Inc.
Revised: February 2013
750-03010-4

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017